Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Krystal Biotech (KRYS) EBIT (2021 - 2025)

Krystal Biotech's EBIT history spans 5 years, with the latest figure at $44.3 million for Q4 2025.

  • For Q4 2025, EBIT rose 6.95% year-over-year to $44.3 million; the TTM value through Dec 2025 reached $161.3 million, up 145.32%, while the annual FY2025 figure was $161.3 million, 145.32% up from the prior year.
  • EBIT for Q4 2025 was $44.3 million at Krystal Biotech, up from $41.5 million in the prior quarter.
  • Across five years, EBIT topped out at $44.3 million in Q4 2025 and bottomed at -$50.2 million in Q1 2022.
  • The 5-year median for EBIT is -$15.0 million (2021), against an average of -$4.8 million.
  • The largest annual shift saw EBIT tumbled 249.91% in 2022 before it surged 1174.84% in 2024.
  • A 5-year view of EBIT shows it stood at -$21.9 million in 2021, then crashed by 58.95% to -$34.8 million in 2022, then surged by 109.34% to $3.2 million in 2023, then soared by 1174.84% to $41.4 million in 2024, then grew by 6.95% to $44.3 million in 2025.
  • Per Business Quant, the three most recent readings for KRYS's EBIT are $44.3 million (Q4 2025), $41.5 million (Q3 2025), and $39.3 million (Q2 2025).